Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a combination vaccine containing tetanus toxoid, diphtheria toxoid, acellular pertussis components (DTaP), and inactivated poliovirus (IPV). It is designed to protect against four serious diseases: tetanus (lockjaw), diphtheria, pertussis (whooping cough), and polio. The vaccine works by stimulating the immune system to produce antibodies against these pathogens without causing disease. It is administered intramuscularly and primarily indicated for children aged 4 to 6 years as part of their routine immunization schedule[2][4][9]. The combination reduces the number of injections required while maintaining strong immunogenicity for all included antigens.
- Brand names
- KinrixQuadracel
- Other names
- DTaP-IPVDTaP + IPVdiphtheria and tetanus toxoids and acellular pertussis adsorbed combined with inactivated poliovirus vaccine
02
Targets
Diphtheria toxinPV3 (Sabin) (Poliovirus type 3 antigen)
Beyond the preview
Go deeper on tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetanus toxoid + diphtheria toxoid + acellular pertussis + inactivated poliovirus vaccine.